UK MHRA extends Casgevy gene-editing approval to children aged five and over
The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.
Event / data period:
Published: · Updated:

Casgevy (exagamglogene autotemcel) was previously restricted to patients aged 12 and above. The therapy edits the patient’s harvested haematopoietic stem cells in a laboratory to reactivate fetal haemoglobin production, before reinfusing them following myeloablative conditioning.
The regulator confirmed that the expansion follows evaluation of clinical trials demonstrating significant reductions in vaso-occlusive pain crises and transfusion dependency in younger age cohorts. Treatment requires specialized cell-therapy centres and rigorous post-infusion monitoring for complications such as cytopenias and infections.
Data
Source publication
Publication of the official approval extension announcement on 29 October 2026.
- · Occurred
MHRA expands Casgevy age authorisation to children aged 5 and over
Regulatory extension granted on 29 October 2026 for pediatric sickle-cell and beta-thalassaemia patients.
Methodology
The date records publication of the cited primary source. Regulatory scope and age indications are stated in the article.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Subject suggested from the title or summary: Healthcare, diseasewww.gov.uk ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- United Kingdom · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.gov.uk ↗